CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 460 enrolled
Drug / intervention
NVA237 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01566604
NCT01566604Phase 3Completed
CompareCT.gov

A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease

Novartis Pharmaceuticals·interventional·Posted Mar 29, 2012·Updated Aug 8, 2014

In Brief

A Phase 3 clinical trial evaluating NVA237 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 460 participants across 32 sites in 4 countries.

Detailed Summary

This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237 in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesChina, India, Philippines, South Korea
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2012
Enrollment StartMar 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.3 years ago

Interventions

NVA237drug

Delivered via a single dose dry powder inhaler

Placebodrug

Delivered via a single dose dry powder inhaler